Sandoz Tries Again With US Pegfilgrastim

04 Apr 2019

Sandoz has resubmitted its application for biosimilar pegfilgrastim to the FDA, having been knocked back with a complete response letter in 2016.

TryAgain — Sandoz Is Making Another Attempt With Its US Pegfilgrastim Biosimilar • Source: Shutterstock

Sandoz has refiled its application for biosimilar pegfilgrastim with the US Food and Drug Administration (FDA), nearly three years after the firm was knocked back by a complete response letter (CRL) in June 2016 for its initial application.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

BGMA Becomes Medicines UK

01 May 2025

• By Dave Wallace

The UK generics and biosimilars industry will now be represented by Medicines UK, the new name for the former British Generic Manufacturers Association.

J&J Denied Injunction Over Private-Label Ustekinumab In US

01 May 2025

• By Dave Wallace

Stelara originator J&J has been denied in its initial attempt to prevent Samsung Bioepis and ustekinumab biosimilar partner Sandoz from selling a private-label version of the product through a PBM in the US.